Lenalidomide and thalidomide: an evolving paradigm for the management of multiple myeloma.
Anderson
Kenneth C
KC
Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Harvard Medical School Boston, MA, USA.
Prince
H Miles
HM
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000276:immunology / Q000627:therapeutic use*; D016207:Cytokines / Q000037:antagonists & inhibitors / Q000276:immunology; D003907:Dexamethasone / Q000276:immunology / Q000627:therapeutic use; D006801:Humans; D007155:Immunologic Factors / Q000276:immunology / Q000627:therapeutic use*; D000077269:Lenalidomide; D009101:Multiple Myeloma / Q000188:drug therapy* / Q000276:immunology; D015398:Signal Transduction / Q000187:drug effects / Q000276:immunology; D013792:Thalidomide / Q000031:analogs & derivatives* / Q000276:immunology / Q000627:therapeutic use*
D016207:Cytokines; D007155:Immunologic Factors; D013792:Thalidomide; D003907:Dexamethasone; D000077269:Lenalidomide